Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 16/20 | 0.71 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.61 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.61 |
| ▸ | BACE2 | Q9Y5Z0 | 9/20 | 0.58 |
| ▸ | CTSD | P07339 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2620236 | 1.00 | BACE1 (0.71) | BACE1KCNH2CYP2D6BACE2CTSD | |
| SCHEMBL8033593 | 0.93 | BACE1 (0.80) | BACE1KCNH2CYP2D6BACE2CTSD | |
| SCHEMBL2620146 | 0.93 | BACE1 (0.80) | BACE1KCNH2CYP2D6BACE2CTSD | |
| SCHEMBL3773173 | 0.93 | BACE1 (0.80) | BACE1KCNH2CYP2D6BACE2CTSD | |
| SCHEMBL3778164 | 0.91 | BACE1 (0.73) | BACE1KCNH2CYP2D6BACE2 | |
| SCHEMBL2620237 | 0.91 | BACE1 (0.73) | BACE1KCNH2CYP2D6BACE2 | |
| SCHEMBL2620235 | 0.90 | BACE1 (0.70) | BACE1KCNH2CYP2D6BACE2 | |
| SCHEMBL8030222 | 0.90 | BACE1 (0.70) | BACE1KCNH2CYP2D6BACE2 | |
| SCHEMBL4363011 | 0.90 | BACE1 (0.70) | BACE1KCNH2CYP2D6BACE2 | |
| SCHEMBL8030450 | 0.90 | BACE1 (0.58) | BACE1KCNH2CYP2D6BACE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2233474-B1 | CONDENSED AMINODIHYDROTHIAZINE DERIVATIVE | EISAI R&D MAN CO LTD (JP) | 2015-08-05 | — | — | EP | disclosed |
| US-8946210-B2 | Fused aminodihydrothiazine derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2015-02-03 | — | — | US | disclosed |
| US-8946211-B2 | Fused aminodihydrothiazine derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2015-02-03 | — | — | US | disclosed |
| US-20130203741-A1 | FUSED AMINODIHYDROTHIAZINE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2013-08-08 | — | — | US | disclosed |
| US-20100317850-A1 | CONDENSED AMINODIHYDROTHIAZINE DERIVATIVE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-12-16 | — | — | US | disclosed |
| EP-2233474-A1 | CONDENSED AMINODIHYDROTHIAZINE DERIVATIVE | Eisai R&D Management Co., Ltd. (JP) | 2010-09-29 | — | — | EP | disclosed |
| US-20090209755-A1 | FUSED AMINODIHYDROTHIAZINE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-08-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130203741-A1 | FUSED AMINODIHYDROTHIAZINE DERIVATIVES | BACE1, APP, BACE2 | BACE1 1/4885KCNH2 2010/4885CYP2D6 1422/4885 |
| US-20090209755-A1 | FUSED AMINODIHYDROTHIAZINE DERIVATIVES | BACE1, APP, BACE2 | BACE1 1/4885KCNH2 2010/4885CYP2D6 1422/4885 |
| US-20100317850-A1 | CONDENSED AMINODIHYDROTHIAZINE DERIVATIVE | BACE1, APP, BACE2 | BACE1 1/4885KCNH2 2256/4885CYP2D6 2480/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.